Type 2 Diabetes Treatment:
Neogliptin
Neogliptin is a promising novel DPP-4 inhibitor (“gliptin”) for the treatment of type 2 diabetes mellitus. Its key advantages include high potency against the target enzyme (DPP-4) and an improved safety profile, particularly regarding cardiotoxicity. Computational screening has demonstrated that Neoglipin exhibits stronger inhibitory activity compared to sitagliptin and vildagliptin, while presenting a lower predicted cardiotoxicity risk than sitagliptin and a safety level comparable to vildagliptin.
In addition, Neoglipin demonstrates chemical stability and improved ADME characteristics compared to vildagliptin, which may have a positive impact on the drug’s pharmacokinetic properties. Collectively, these attributes make this molecule an attractive candidate: in essence, Neoglipin combines the best qualities of existing gliptins while offering reduced side effects.
Partnerships & Alliances:
​Drawing on our advantages, as well as many years of experience in developing innovative drugs, we assess the probability of successful tests and the launch of our project onto the market as very high.
​
-
We are currently looking to build alliances & partnerships with potential investors to promote our clinical research and prepare for a potential launch onto market.
-
If you are interested in this opportunity, please use our contact form here.